natgillin/translations-raw huggingface dataset:
Dry mouth Abdominal pain 
Bolezni prebavil pogosti navzea diareja bruhanje občasni suha usta bolečina v trebuhu
Respiratory, thoracic and mediastinal disorders 
Bolezni jeter, žolčnika in žolčevodov neznana pogostnost zvišane vrednosti jetrnih encimov
Nasal congestion Pharyngo laryngeal pain 
Bolezni dihal, prsnega koša in mediastinalnega prostora občasni zamašen nos bolečine v faringo-laringealnem prostoru
Package leaflet: Information for the user Zyclara 3.75% cream 
Navodilo za uporabo Zyclara 3,75 % krema imikvimod
Uncommon (≥ 1/1,000 to < 1/100); 
Občasni (pojavijo se pri 1od 100 bolnikov)
The clinical significance of these results is not known. 
Klinični pomen teh rezultatov ni znan.
In this study the majority of patients had a vital capacity less than 60%. 
V tej študiji je imela večina bolnikov vitalno kapaciteto manj kot 60 %.
The mode of action is unclear. 
Način delovanja ni jasen.
The recommended dose is one tablet, twice a day. 
Priporočeni odmerek je ena tableta, dvakrat na dan.
The elimination half-life ranges from 9 to 15 hours. 
Eliminacijski razpolovni čas je od 9 do 15 ur.
However, the power of this study to detect differences between treatment groups was low. 
Vendar je bila moč te študije za odkrivanje razlik med skupinama majhna.
No significant increased benefit can be expected from higher daily doses. 
Od večjih dnevnih odmerkov ni mogoče pričakovati pomembno večje koristi.
These increases could be associated with jaundice. 
To zvišanje je lahko povezano z zlatenico.
If any of the above applies to you, or if you are not sure, tell your doctor who will decide what to do. 
Če karkoli od navedenega velja za vas, ali če niste prepričani, povejte svojemu zdravniku, ki se bo odločil kaj storiti.
In case of overdose, treatment is symptomatic and supportive. 
V primeru prevelikega odmerjanja je zdravljenje simptomatsko in podporno.
The volume of distribution of riluzole is about 245 ± 69 L (3.4 L/kg). 
Volumen porazdelitve riluzola je približno 245 ± 69 l (3,4 l/kg).
If you forget to take your tablet, leave out that dose completely and take the next tablet at the usual time. 
Če pozabite vzeti tableto, popolnoma izpustite ta odmerek in vzemite naslednjo tableto ob običajnem času.
Date of first authorisation: 07 May 2012 Date of latest renewal: {DD month YYYY} 
Datum prve odobritve: 07 maj 2012 Datum zadnjega podaljšanja: 09. januar 2017
The tablets should be taken by mouth, every 12 hours, at the same time of the day each day (e.g. in the morning and evening). 
Tablete morate zaužiti, na 12 ur, vsak dan ob istem dnevnem času (npr. zjutraj in zvečer).
Sanofi Winthrop Industrie 56, Route de Choisy au Bac 60205 Compiègne France 
Sanofi Winthrop Industrie 56, Route de Choisy au Bac 60205 Compiègne Francija
Undesirable effects ranked under headings of frequency are listed below, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). 
Spodaj našteti neželeni učinki so razvrščeni po pogostosti, po naslednjem dogovoru: zelo pogosti (≥1/10), pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov).
Readministration of riluzole to patients in this situation cannot be recommended. 
Ponovne uporabe riluzola pri bolnikih v takšnih okoliščinah ni mogoče priporočiti.
Riluzole is eliminated mainly in the urine. 
Riluzol se izloči predvsem v urinu.
This isolated finding was not noted in any other study or species. 
Ta osamljeni izsledek se ni pojavil v nobeni drugi študiji in pri nobeni drugi živalski vrsti.
No malformations were seen in animal reproductive studies. 
V reprodukcijskih študijah na živalih niso opazili malformacij.
Riluzole Zentiva 
Riluzol Zentiva
Riluzole is about 97% protein bound and it binds mainly to serum albumin and to lipoproteins. 
Riluzol je približno 97-odstotno vezan na beljakovine in se veže predvsem na serumski albumin in lipoproteine.
If you are less than 18 years of age, the use of Riluzole Zentiva is not recommended because there is no information available in this population. 
Če ste mlajši od 18 let, uporaba zdravila Riluzol Zentiva ni priporočljiva, saj ni na voljo nobenih informacij za to populacijo.
Patients should be warned to report any febrile illness to their physicians. 
Bolnikom je treba naročiti, da morajo o vsaki febrilni bolezni obvestiti svojega zdravnika.
Your doctor may want to take a blood sample to check the number of white blood cells, which are important in fighting infections. 
Zdravnik vam bo morda hotel odvzeti vzorec krvi in preveriti število belih krvnih celic, ki so pomembne pri premagovanju okužb.
U kabelovny 130 102 37 Prague 10 Czech Republic 
U kabelovny 130 102 37 Prague 10 Češka republika
Only 2% of a riluzole dose was recovered unchanged in the urine. 
Le 2 % odmerka riluzola se v urinu izloči nespremenjenega.
On the basis of these data, and taking into consideration the negative studies on the carcinogenesis of riluzole in the mouse and rat, the genotoxic effect of this metabolite is not considered to be of relevance in humans. 
Na podlagi teh podatkov in upoštevaje negativne rezultate študij o karcinogenosti riluzola pri miših in podganah genotoksični učinki tega presnovka ne veljajo za pomembne pri ljudeh.
The recommended daily dose in adults or older people is 100 mg (50 mg every 12 hours). 
Priporočeni dnevni odmerek za odrasle in starejše ljudi je 100 mg (50 mg na 12 ur).
Patients should be warned about the potential for dizziness or vertigo, and advised not to drive or operate machinery if these symptoms occur. 
Bolnike je treba opozoriti na možnost omotice ali vrtoglavice in jim svetovati, naj ne vozijo in ne upravljajo s stroji, če se pojavita ta simptoma.
Study data indicate that Asian patients may be more susceptible to liver function test abnormalities3.2% (194/5995) of Asian patients and 1.8% (100/5641) of Caucasian patients. 
Podatki iz študije kažejo, da so bolniki azijskega porekla bolj dovzetni za nenormalnosti v testih jetrnih funkcij: 3,2 % (194/5995) bolnikov azijskega porekla in 1,8 % (100/5641) bolnikov kavkaškega porekla.
It is not known whether riluzole is excreted in human milk. 
Ni znano, ali se riluzol pri človeku izloča v mleko.
If you think you may be pregnant, or if you intend to breast-feed, ask your doctor for advice before taking Riluzole Zentiva. 
Če mislite, da ste noseči, ali če nameravate dojiti, se posvetujte s svojim zdravnikom preden vzamete zdravilo Riluzol Zentiva.
In lactating rats, 14C-riluzole was detected in milk. 
Pri doječih podganah so 14C-riluzol odkrili v mleku.
If you take too many tablets, contact your doctor or the nearest hospital emergency department immediately. 
Če ste vzeli preveč tablet, se nemudoma posvetujte s svojim zdravnikom ali oddelkom najbližje nujne zdravniške pomoči.
In the majority of the reported cases, symptoms resolved after medicinal product discontinuation and symptomatic treatment. 
V večini opisanih primerov so simptomi po prenehanju uporabe zdravila in simptomatskem zdravljenju izginili.
Based on pharmacokinetic data, there are no special instructions for the use of Riluzole Zentiva in this population. 
Na temelju farmakokinetičnih podatkov ni posebnih navodil za uporabo zdravila Riluzol Zentiva v tej populaciji.
All these findings were noted at doses which were 2-10 times higher than the human dose of 100 mg/day. 
Vse te ugotovitve so zabeležili pri odmerkih, 2- do 10-krat večjih od odmerka 100 mg/dan, ki se uporablja pri človeku.
56 film-coated tablets 28 film-coated tablets 98 film-coated tablets 112 film-coated tablets 168 film-coated tablets 
56 filmsko obloženih tablet 28 filmsko obloženih tablet 98 filmsko obloženih tablet 112 filmsko obloženih tablet 168 filmsko obloženih tablet
Standard tests for genotoxicity performed with riluzole were negative. 
Standardni testi genotoksičnosti, narejeni z riluzolom, so bili negativni.
You MUST NOT take Riluzole Zentiva if you are or think you may be pregnant, or if you are breast-feeding. 
Zdravila Riluzol Zentiva NE SMETE jemati, če ste noseči ali mislite, da ste noseči ali če dojite.
In dogs, haemolytic anaemia was observed. 
Pri psih so opažali hemolitično anemijo.
Clinical experience with riluzole in pregnant women is lacking. 
Kliničnih izkušenj z riluzolom pri nosečnicah ni.
The rate and extent of absorption is reduced when riluzole is administered with high-fat meals (decrease in Cmax of 44%, decrease in AUC of 17%). 
Hitrost in delež absorpcije se po uporabi riluzola z zelo mastnimi obroki zmanjšata (zmanjšanje Cmax za 44 % in zmanjšanje površine pod krivuljo plazemskih koncentracij (AUC) za 17 %).
Intensive testing in seven other standard in vitro or in vivo assays did not show any genotoxic potential of the metabolite. 
Intenzivno testiranje v sedmih drugih standardnih preizkusih in vivo in in vitro ni pokazalo nobenega genotoksičnega potenciala tega presnovka.
Tests on the major active metabolite of riluzole gave positive results in two in vitro tests. 
Testi glavnega aktivnega presnovka riluzola so v dveh testih in vitro dali pozitivne rezultate.
Riluzole Zentiva has not been shown to be effective in the late stages of ALS. 
Zentiva bilo učinkovito v poznih stadijih ALS.
Riluzole Zentiva stops the release of glutamate and this may help in preventing the nerve cells being damaged. 
Zdravilo Riluzol Zentiva prepreči sproščanje glutamata, kar najbrž pomaga preprečevati poškodbo živčnih celic.
Riluzole is rapidly absorbed after oral administration with maximal plasma concentrations occurring within 60 to 90 minutes (Cmax=173 ± 72 (sd) ng/ml). 
Po peroralni uporabi se riluzol hitro absorbira in doseže najvišjo koncentracijo v 60 do 90 minutah (Cmax = 173 ± 72 (sd) ng/ml).
There have been no clinical studies to evaluate the interactions of riluzole with other medicinal products. 
Kliničnih študij za oceno medsebojnega delovanja riluzola z drugimi zdravili ni bilo.
ALT levels should be measured more frequently in patients who develop elevated ALT levels. 
ALT je treba pogosteje določati pri bolnikih, ki se jim ALT zviša.
See sections 4.3, 4.4 and 5.2 
Okvarjeno delovanje jeter Glejte poglavja 4.3, 4.4 in 5.2.
Therefore, Riluzole Zentiva should not be used in patients with any other form of motor neurone disease. 
Zato se zdravila Riluzol Zentiva ne sme uporabljati pri bolnikih z drugimi oblikami bolezni motoričnega nevrona.
Riluzole is extensively distributed throughout the body and has been shown to cross the blood brain barrier. 
Riluzol se izdatno porazdeljuje po telesu; dokazano je, da prehaja krvno-možgansko pregrado.
Manufacturers 
Izdelovalci
Increased alanine aminotransferase usually appeared within 3 months after the start of therapy with riluzole; they were usually transient and levels returned to below twice the ULN after 2 to 6 months while treatment was continued. 
Zvišanje alanin-aminotransferaze se je ponavadi pojavilo v 3 mesecih po začetku zdravljenja z riluzolom; ponavadi je bilo prehodno in raven se je med nadaljevanjem zdravljenja znižala na manj kot 2 kratno ULN po 2 do 6 mesecih.
In a parallel group study designed to assess the efficacy and safety of riluzole in patients at a late stage of the disease, survival time and motor function under riluzole did not differ significantly from that of placebo. 
V študiji vzporednih skupin za oceno učinkovitosti in varnosti riluzola pri bolnikih v poznem stadiju bolezni se čas preživetja in motorična funkcija ob uporabi riluzola nista bistveno razlikovala od tistih s placebom.
Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free. 
Preživetje je definirano kot obdobje, ki ga bolniki preživijo brez intubacije za mehanično ventilacijo in brez traheotomije.
Fertility studies in rats revealed slight impairment of reproductive performance and fertility at doses of 15 mg/kg/day (which is higher than the therapeutic dose), probably due to sedation and lethargy. 
Plodnost Študije plodnosti pri podganah so pokazale rahlo poslabšanje reproduktivne sposobnosti in plodnosti pri odmerkih 15 mg/kg/dan (kar je več od terapevtskega odmerka), verjetno zaradi sedacije in letargije.
This metabolite is rapidly glucuronoconjugated to O- and N-glucuronides. 
Ta presnovek se hitro glukuronokonjugira v O- in N-glukuronide.
if you experience cough or difficulties in breathing, as this may be a sign of lung disease (called interstitial lung disease). 
- če se vam pojavi kašelj ali težko dihanje, kajti to je lahko znak bolezni pljuč (imenujemo jo intersticijska bolezen pljuč)
Safety and efficacy of Riluzole Zentiva has only been studied in ALS. 
Varnost in učinkovitost zdravila Riluzol Zentiva sta bili raziskani le pri ALS.
Survival, as defined in the second paragraph of section 4.1, was significantly extended for patients who received riluzole as compared to patients who received placebo. 
Preživetje, kot je definirano v drugem odstavku poglavja 4.1, je bilo značilno daljše pri bolnikih, ki so dobivali riluzol, kot pri tistih, ki so dobivali placebo.
The effect of riluzole 50 mg/day was not statistically significant compared to placebo and the effect of 200 mg/day was essentially comparable to that of 100 mg/day. 
Učinek riluzola 50 mg/dan se ni statistično značilno razlikoval od placeba, učinek odmerka 200 mg/dan pa je bil primerljiv učinku odmerka 100 mg/dan.
In rats, riluzole decreased the pregnancy rate and the number of implantations at exposure levels at least twice the systemic exposure of humans given clinical therapy. 
Pri podganah je riluzol zmanjšal delež brejosti in število implantacij ob izpostavljenosti, vsaj dvakrat tolikšni kot je sistemska izpostavljenost človeka med kliničnim zdravljenjem.
Patients who are pregnant or breast-feeding. 
Bolnice, ki so noseče ali dojijo.
Pharmacotherapeutic group: other nervous system drugs, ATC code: N07XX02. 
5.1 Farmakodinamične lastnosti Farmakoterapevtska skupina: druga zdravila z delovanjem na živčevje, oznaka ATC: N07XX02.
In this study, the efficacy was assessed on inability to walk alone, loss of upper limb function, tracheostomy, need for artificial ventilation, gastric tube feeding or death. 
V tej študiji so bila merila za presojo učinkovitosti nezmožnost za samostojno hojo, izguba funkcije zgornjih okončin, traheostomija, potreba po umetni ventilaciji, hranjenje po želodčni sondi ali smrt.
Meta-analysis including this study and those described above showed a less striking effect on survival for riluzole as compared to placebo although the differences remained statistically significant. 
Metaanaliza, ki je zajela to in zgoraj opisane študije, je za riluzol pokazala manj izrazit vpliv na preživetje v primerjavi s placebom, vendar so razlike ostale statistično značilne.
The destruction of nerve cells in motor neurone disease may be caused by too much glutamate (a chemical messenger) in the brain and spinal cord. 
Do propada živčnih celic pri bolezni motoričnega nevrona lahko pride zaradi prevelike količine glutamata (kemijskega prenašalca) v možganih in v hrbtenjači.
Coating: hypromellose, macrogol 6000, titanium dioxide (E171). 
Obloga: hipromeloza, makrogol 6000 in titanov dioksid (E171).
Baseline elevations of several liver function tests (especially elevated bilirubin) should preclude the use of riluzole (see section 4.8). 
Izhodiščno zvišanje več jetrnih funkcijskih testov (zlasti zvišan bilirubin) izključuje uporabo riluzola (glejte poglavje 4.8).
EU/1/12/768/001 - 56 film-coated tablets EU/1/12/768/002 - 28 film-coated tablets EU/1/12/768/003 - 98 film-coated tablets EU/1/12/768/004 - 112 film-coated tablets EU/1/12/768/005 - 168 film-coated tablets 
EU/1/12/768/001- 56 filmsko obloženih tablet EU/1/12/768/002 - 28 filmsko obloženih tablet EU/1/12/768/003 - 98 filmsko obloženih tablet EU/1/12/768/004 - 112 filmsko obloženih tablet EU/1/12/768/052 - 168 filmsko obloženih tablet
There is no evidence that Riluzole Zentiva exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. 
Ni dokazov, da bi zdravilo Riluzol Zentiva terapevtsko učinkovalo na motorično funkcijo, pljučno funkcijo, fascikulacije, mišično moč ali motorične simptome.
Riluzole should be prescribed with care in patients with a history of abnormal liver function, or in patients with slightly elevated serum transaminases (ALT/SGPT; AST/SGOT up to 3 times the upper limit of the normal range (ULN)), bilirubin and/or gamma-glutamyl transferase (GGT) levels. 
Previdnost je potrebna pri predpisovanju riluzola bolnikom z anamnezo motenega delovanja jeter ali bolnikom z nekoliko zvišano ravnjo serumskih transaminaz (ALT/SGPT, AST/SGOT do vrednosti, ki je enaka 3-kratni zgornji meji normalne vrednosti (ULN)), bilirubina in/ali gama-glutamiltransferaze
Riluzole Zentiva is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS). 
Zdravilo Riluzol Zentiva je indicirano za podaljšanje življenja ali časa do mehanične ventilacije pri bolnikih z amiotrofično lateralno sklerozo (ALS).
Hepatic disease or baseline transaminases greater than 3 times the upper limit of normal. 
Bolezen jeter ali izhodiščna raven transaminaz, ki več kot 3-krat presega zgornjo normalno mejo.
The tablets are film-coated, capsule-shaped and white. 
Tablete so filmsko obložene, imajo kapsulam podobno obliko in so bele barve.
Riluzole Zentiva is not recommended for use in patients with impaired renal function, as studies at repeated doses have not been conducted in this population (see section 4.4). 
Zdravila Riluzol Zentiva ni priporočljivo uporabljati pri bolnikih z okvarjenim delovanjem ledvic, ker v tej populaciji ni bilo študij s ponavljajočimi odmerki (glejte poglavje 4.4).
In vitro studies using human liver microsomal preparations suggest that CYP 1A2 is the principal isozyme involved in the initial oxidative metabolism of riluzole. 
Študije in vitro z uporabo mikrosomskih preparatov človeških jeter kažejo, da je CYP 1A2 glavni izoencim, ki sodeluje v uvodni oksidativni presnovi riluzola.
A clinical study conducted to evaluate the pharmacokinetics of riluzole and its metabolite N-hydroxyriluzole following repeated oral administration twice daily for 8 days in 16 healthy Japanese and 16 Caucasian adult males showed in the Japanese group a lower exposure of riluzole (Cmax 0.85 [90% CI 0.68-1.08] and AUC inf. 0.88 [90% CI 0.69-1.13]) and similar exposure to the metabolite. 
Za oceno farmakokinetike riluzola in njegovega presnovka N-hidroksiriluzola po ponavljajočem peroralnem jemanju dvakrat na dan 8 dni, so pri 16 zdravih japonskih in 16 zdravih kavkaških odraslih moških izvedli klinično študijo, ki je pri japonskih moških pokazala nižjo izpostavljenost riluzolu (Cmax 0,85 [90 % IZ 0,68-1,08] in AUCinf.
Treatment with Riluzole Zentiva should only be initiated by specialist physicians with experience in the management of motor neurone diseases. 
Zdravljenje z zdravilom Riluzol Zentiva sme uvesti samo zdravnik specialist z izkušnjami v zdravljenju bolezni motoričnega nevrona.
Film-coated tablet The tablets are capsule-shaped, white and engraved with “RPR 202” on one side. 
filmsko obložena tableta Tablete imajo kapsulam podobno obliko, so bele barve in imajo na eni strani vrezan napis "RPR 202".
The overall urinary excretion accounts for about 90% of the dose. 
V celoti se v urinu izloči približno 90 % odmerka.
About 90% of the dose is absorbed and the absolute bioavailability is 60 ± 18%. 
Absorbira se okrog 90 % odmerka in absolutna biološka uporabnost je
Although the pathogenesis of ALS is not completely elucidated, it is suggested that glutamate (the primary excitatory neurotransmitter in the central nervous system) plays a role for cell death in the disease. 
Patogeneza ALS sicer ni povsem pojasnjena, vendar domnevajo, da igra vlogo pri odmiranju celic pri tej bolezni glutamat (primarni ekscitatorni nevrotransmitor v osrednjem živčevju).
Clinical trials have demonstrated that Riluzole Zentiva extends survival for patients with ALS (see section 5.1). 
Klinična preskušanja so pokazala, da zdravilo Riluzol Zentiva podaljša preživetje bolnikov z ALS (glejte poglavje 5.1).
The median survival time was 17.7 months versus 14.9 months for riluzole and placebo, respectively. 
Mediano preživetje je bilo ob riluzolu 17,7 mesecev in ob placebu 14,9 mesecev.
The report of a febrile illness should prompt physicians to check white blood cell counts and to discontinue riluzole in case of neutropenia (see section 4.8). 
Po obvestilu o febrilni bolezni mora zdravnik preveriti belo krvno sliko in v primeru nevtropenije uporabo riluzola prekiniti (glejte poglavje 4.8).
In patients treated with riluzole 100 mg/day, survival was significantly higher compared to patients who received placebo. 
zdravljenih z riluzolom 100 mg/dan, je bilo preživetje značilno večje kot pri bolnikih, ki so dobivali placebo.
Each tablet contains 50 mg of riluzole and is engraved with “RPR 202” on one side. 
50 mg riluzola in ima na eni strani vrezan napis "RPR 202".
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder: 
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
Riluzole is proposed to act by inhibiting glutamate processes. 
Riluzol naj bi deloval z zavrtjem dogajanj, povezanih z glutamatom.
If you forget to take Riluzole Zentiva 
Če ste pozabili vzeti zdravilo Riluzol Zentiva
The pharmacokinetic parameters of riluzole after multiple dose administration (4.5 days of treatment at 50 mg riluzole bid) are not affected in the older people (>70 years). 
Farmakokinetični parametri riluzola se po večkratnem odmerjanju (4,5 dni zdravljenja s 50 mg riluzola dvakrat na dan) pri starejših (> 70 let) ne spremenijo.
Each film-coated tablet contains 50 mg of riluzole. 
Ena filmsko obložena tableta vsebuje 50 mg riluzola.
Other medicines and Riluzole Zentiva 
Druga zdravila in zdravilo Riluzol Zentiva
Cases of interstitial lung disease have been reported in patients treated with riluzole, some of them were severe (see section 4.8). 
Med zdravljenjem z riluzolom so bili opisani primeri intersticijske bolezni pljuč; nekateri od njih so bili hudi (glejte poglavje 4.8).
The metabolites identified in urine are three phenolic derivatives, one ureido-derivative and unchanged riluzole. 
V urinu so določili tri fenolne presnovke, enega ureidnega in nespremenjeni riluzol.
Riluzole did not show any carcinogenicity potential in either rats or mice. 
Riluzol pri podganah in miših ni pokazal karcinogenega potenciala.
If you take more Riluzole Zentiva than you should 
Če ste vzeli večji odmerek zdravila Riluzol Zentiva, kot bi smeli
Riluzole Zentiva is used in patients with amyotrophic lateral sclerosis (ALS). 
Zdravilo Riluzol Zentiva uporabljamo pri bolnikih z amiotrofično lateralno sklerozo (ALS).
In a dose-ranging trial, 959 patients with ALS were randomised to one of four treatment groups: riluzole 50, 100, 200 mg/day, or placebo and were followed-up for 18 months. 
V preskušanju razpona odmerjanja so 959 bolnikov z ALS randomizirali v eno od štirih terapevtskih skupin - riluzol 50, 100, 200 mg/dan ali placebo - in jih spremljali 18 mesecev.
The AUC of riluzole after a single oral dose of 50 mg increases by about 1.7 fold in patients with mild chronic liver insufficiency and by about 3 fold in patients with moderate chronic liver insufficiency. 
Po enkratnem peroralnem odmerku 50 mg se je AUC riluzola pri bolnikih z blago kronično insuficienco jeter zvečal za približno 1,7-krat in pri bolnikih z zmerno kronično insuficienco jeter za približno 3-krat.
Contents of the pack and other information What Riluzole Zentiva contains 
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Riluzol Zentiva
What Riluzole Zentiva is and what it is used for What you need to know before you take Riluzole Zentiva How to take Riluzole Zentiva Possible side effects 
Kaj je zdravilo Riluzol Zentiva in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Riluzol Zentiva Kako jemati zdravilo Riluzol Zentiva